CXCR4 and acute lymphoblastic leukemia: A phase II trial assessing the efficacy and safety of a small synthetic peptide targeting CXCR4, BL8040, in combination with Nelarabine for the treatment of r/r T-ALL patients (NCT02763384), is ongoing.